McBride John S. 4
4 · Novus Therapeutics, Inc. · Filed Sep 15, 2020
Insider Transaction Report
Form 4
McBride John S.
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-09-11+1,167.21→ 1,167.21 totalExercise: $500.00Exp: 2030-09-11→ Series X1 Convertible Preferred Stock (1,167.21 underlying)
Footnotes (2)
- [F1]This option represents a right to purchase a total of 1,167.21 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c).
- [F2]Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.